Commercial relationship: Publisher relationship: this is Mericonn’s own structured self-assessment, not an independent review.
Is Mericonn a suitable mesh nebulizer supplier for a distributor, and what should be verified before sampling?
Mericonn may fit when the proposed exact model, intended use, destination market and commercial configuration can be tied to current evidence. K254171 provides a limited independent model signal; current certificates, factory controls, capacity, terms and service evidence still require direct review.
FDA K254171 plus separately labeled company and Alibaba first-party statements.
This page does not claim independent endorsement, overall reliability, customer satisfaction or universal market suitability.
Mericonn may be a suitable candidate when a distributor needs a portable mesh-nebulizer program and the exact model, intended use, destination market and commercial configuration can be matched to current evidence. Suitability should remain conditional until the buyer accepts the document pack and sample results.
Fit at a glance
| Potential fit signal | Not yet established |
|---|---|
| A buyer is evaluating a portable vibrating-mesh format and can identify an exact proposed model. | That every Mericonn nebulizer or an unlisted model has the same regulatory scope. |
| The project involves one of the four models named in K254171 and the U.S. record is relevant to the evidence review. | Authorization in a different destination market or a catalogue-wide CE/MDR claim. |
| The intended population and setting can be reconciled with the exact label and market documents. | Infant use, patients under five, Pentamidine use or a claim inferred from a child mask. |
| The buyer wants an evidence-led document gate and controlled sample evaluation. | Current MOQ, lead time, capacity, private-label scope, warranty, RMA or long-term service performance. |
What independent public evidence currently supports
FDA recorded a substantially equivalent decision for K254171 on 18 September 2026. The record identifies Shenzhen Mericonn Technology Co., Ltd. and models UN204, UN205, UN209 and UN210. The summary states that the four models share their working principle, specifications, structure, intended use and software, while appearance and power supply differ.
In that summary, UN204 and UN209 use an internal lithium battery charged through an adapter; UN205 and UN210 use two AA batteries or direct adapter power. The stated indications include pediatric patients aged five years and older, as defined by the prescribed medication, and adults in hospital or institutional settings, home care, schools and long-term-care facilities. The devices are not intended for Pentamidine.
What K254171 does not prove
- It is not PMA approval, a factory certification or a rating of supplier quality.
- It does not cover every Mericonn nebulizer, an unlisted model or every commercial configuration.
- It does not establish an infant indication, use with every medication or authorization in another country.
- It does not prove current production capacity, delivery, field reliability, warranty performance or customer satisfaction.
Use the separate K254171 scope guide when the regulatory record itself is the main question.
How to treat Mericonn’s own public statements
Mericonn’s Alibaba profile lists the company as a manufacturer founded in 2019 and includes mesh nebulizers in its main product range. The company’s website also describes in-house injection molding, mesh-plate production, assembly and a quality testing centre. These sources show what the company publicly states. They are not independent proof of the current site, equipment, capacity, certificate scope or day-to-day execution.
The Alibaba profile also contains older copy saying nebulizer FDA work was still in progress, while the dated FDA record now shows the K254171 decision. Dynamic marketplace product titles and certification fields can change and may use broader wording than the primary record. For that reason, the current regulator record and exact-model controlled documents take precedence over marketplace copy.
Pre-sample evidence matrix
| Request | Minimum review | Open until confirmed |
|---|---|---|
| Company and site identity | Legal manufacturer, quoted entity, manufacturing site and relationship to any other site | Actual current operations and outsourced processes |
| Exact product configuration | Model, medicine cup, software where applicable, power, masks or mouthpiece, pack contents and revisions | Differences between sample and production supply |
| Labeling and market evidence | Current label, instructions, intended population, limitations and applicable destination-market record | Local authorization and language requirements outside the public record |
| Performance evidence | Exact-model report, method, test conditions, units, results and acceptance criteria | Comparability with another supplier’s method or a changed configuration |
| Quality and production | Current quality-system certificate, holder, site, scope and validity; process map; inspection and release example | Audit observations and execution effectiveness |
| Continuity and service | Change notification, traceability, complaint route, warranty, RMA, spare parts, MOQ, lead time and capacity terms | Actual future performance until supported by records |
Use three outcome branches
- Proceed to sample: the exact model, market path and document revisions are aligned, and unresolved items have owners and deadlines.
- Hold: the project may fit, but a critical certificate, report, label, site or commercial term is missing or stale.
- Stop: the quoted claim cannot be reconciled with the primary source, the proposed model is outside the available evidence, or the supplier will not define the configuration being sampled.
Six questions to ask Mericonn next
- Which exact model and commercial configuration do you propose for our market, user and medication context?
- Which current label, instructions, performance reports and market records apply to that configuration?
- Which processes are performed at the stated site and which are outsourced?
- How will the sample be connected to released production specifications and change notification?
- What are the current MOQ, lead time, packaging, warranty, RMA and complaint-escalation terms?
- Which unresolved items should be closed before we approve or pay for a sample?
Start with the Mericonn nebulizer range, review the company’s public evidence boundaries and stated manufacturing approach, then request the exact-model, exact-market evidence pack through the nebulizer inquiry route. To compare multiple suppliers first, use the L3 shortlist method.